Page 4 - Flipbook

Program Objectives

By the end of this program, participants can expect to:

• examine the PROPEL phase III study evaluating the efficacy, safety, and tolerability of

olaparib versus placebo when given in addition to abiraterone to patients with

metastatic castration-resistant prostate cancer (mCRPC) who have not received prior

chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant

prostate cancer (mCRPC) (first-line setting)

• review the MAGNITUDE A Phase 3 Randomized, Placebo-controlled, Double-blind Study

of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus

Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer

• discuss the Clinical Implications of Data in Practice